Drug Trial Radar · NCT07845578
A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 25, 2026
Primary completion
Sep 11, 2027
Study completion Sep 11, 2027
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the effect of semaglutide on gastric emptying in people with obesity. Participants will receive either semaglutide or placebo, and the treatment assigned will be decided by chance. Semaglutide is a medicine that doctors can already prescribe, while placebo contains no active medicine.
Conditions
- Obesity
- Overweight
Interventions
SemaglutideDrug
Semaglutide will be administered in the thigh, abdomen, or upper arm of body part.
Placebo semaglutideDrug
Placebo matched to semaglutide will be administered in the thigh, abdomen, or upper arm of body part.
ParacetamolDrug
Paracetamol is administered orally as part of a standardised meal to assess gastric emptying through pharmacokinetic evaluation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC,para: The area under the paracetamol plasma concentration-time curve following a standardised mealTime frame: Day 177
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of Graz
Graz, Austria · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.